REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal

BACKGROUND: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal. METHODS: Retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Batista, S., Nunes, C. C., Cerqueira, J. J., Martins Silva, Ana, Correia de Sá, J., Ferreira, J., Mendonça, M. T., Pinheiro, J., Salgado, V., Correia, A. S., Sequeira, J., Costa, A., Sousa, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043899/
https://www.ncbi.nlm.nih.gov/pubmed/32997282
http://dx.doi.org/10.1007/s10072-020-04726-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043899/
https://www.ncbi.nlm.nih.gov/pubmed/32997282
http://dx.doi.org/10.1007/s10072-020-04726-6

Ejemplares similares